Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Nanomaterials (Basel) ; 9(10)2019 Oct 21.
Artigo em Inglês | MEDLINE | ID: mdl-31640135

RESUMO

For the enhancement of the anticorrosion and antibacterial performance of the biomedical alloy Ti6Al4V, a novel Cu incorporated multilayer Ta2O5ceramic composite coating Cu-Ta2O5/Ta2O5/Ta2O5-TiO2/TiO2/Ti (coating codeCu-MTa2O5) was developed by radio frequency (RF) and direct current (DC) reactive magnetron sputtering. Meanwhile, to better display the multilayer Ta2O5 coating mentioned above, a monolayer Ta2O5 ceramic coating was deposited onto the surface of Ti6Al4V alloy as a reference. The surface morphology, microstructure, phase constituents, and elemental states of the coating were evaluated by atomic force microscopy, scanning electron microscopy, X-ray diffraction, and X-ray photoelectron spectroscopy, respectively. The adhesion strength, wettability, anticorrosion and antibacterial properties of the coating were examined by a scratch tester, contact angle measurement, electrochemical workstations, and plate counting method, respectively. The results showed that the deposited coatings were amorphous and hydrophobic. Cu doped into the Ta2O5 coating existed as CuO and Cu2O. A Ta2O5-TiO2/TiO2/Ti multi-interlayer massively enhanced the adhesion strength of the coating, which was 2.9 times stronger than that of the monolayer Ta2O5coating. The multilayer Cu-MTa2O5 coating revealed a higher corrosion potential and smaller corrosion current density as compared to the uncoated Ti6Al4V, indicating the better anticorrosion performance of Ti6Al4V. Moreover, a 99.8% antibacterial effect of Cu-MTa2O5 coated against Staphylococcus aureuswas obtained.

2.
Medicine (Baltimore) ; 96(9): e5795, 2017 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-28248850

RESUMO

BACKGROUD: The aim of the study was to evaluate the effect of early parenteral iron supplementation combined erythropoietin for prevention of anemia in preterm infants. METHODS: In total, 96 preterm infants were randomly assigned to 3 groups: a control group receiving standard parenteral nutrition (group 1: n = 31), an iron-supplemented group (group 2: IS, n = 33), and an iron-supplemented combined erythropoietin group (group 3: IS+EPO, n = 32). The primary objective was to assess hemoglobin (Hb) levels. The secondary objectives included assessment of red blood cell counts (RBC), mean cell volume (MCV), serum iron, ferritin, percentages of reticulocyte (RET), total iron binding capacity (TIBC) and oxidative stress, which was assessed by measuring plasma levels of malondialdehyde and superoxide dismutase at baseline and at 2 weeks. The blood routine indices including Hb, RBC, MCV, and percentages of RET were measured at corrected age of 1 and 3 months. RESULTS: At 2 weeks of life, the percentages of reticulocyte in group 2 and group 3 were significantly higher than those in group 1 (2.1±0.4, 2.5±0.3, and 1.7±0.3, respectively, P < 0.001, P<0.001), whereas TIBC were significantly lower than those in group 1 (36.7±4.6, 36.0±4.7, and 41.6 ±â€Š5.2 respectively, P = 0.011, P = 0.006). There were no significant differences in RBC counts, the levels of hemoglobin, ferritin, malondialdehyde, and superoxide dismutase among the 3 groups at 2weeks of life. RBC, Hb, MCV, body weight, body length, and head circumference at a corrected age of 1 month did not differ among 3 groups. At corrected age of 3months, more infants in the control group had abnormal Hb and MCV levels (Hb levels: 114.3 ±â€Š21.3, 123.7 ±â€Š31.6, and 125.1 ±â€Š21.2, P = 0.021, P = 0.034, respectively; MCV: 74.1 ±â€Š3.5, 78.3 ±â€Š4.7 and 79.1 ±â€Š5.2, P = 0.017, P = 0.012, respectively), whereas cases of oral iron, cases of breastfeeding, RBC, body weight, body length, and head circumference were not different among 3 groups. CONCLUSION: Early parenteral iron supplementation combined erythropoietin in preterm infants improved the percentages of reticulocyte, decreased total iron binding capacity, and improved the Hb and MCV levels at 3 months of age. Early parenteral iron supplementations with EPO were beneficial for the preterm infants.


Assuntos
Anemia/tratamento farmacológico , Eritropoetina/administração & dosagem , Ferro/administração & dosagem , Feminino , Humanos , Recém-Nascido , Recém-Nascido Prematuro , Masculino
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA